newsfilter
← Latest News
Business Wire·

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts Session Oral and poster